This is a prospective pilot study, the primary aim of which is to determine whether the
presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated
evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after
immunotherapy and other treatments.